STAT+: SalioGen Therapeutics hit by layoffs, as gene-editing biotechs continue to struggle
STAT
OCTOBER 13, 2024
SalioGen Therapeutics, a company that raised $135 million to develop a new gene-editing technology, has instituted widespread layoffs and is scaling back its ambitions, according to a person familiar with the situation and employee posts on social media. It is the latest in a series of retrenchments by high-profile gene-editing companies. A spokesperson for SalioGen declined to comment.
Let's personalize your content